Home › Funds › Invenomic Capital Management LP › VTRS
Invenomic Capital Management LP position in VTRS
VIATRIS INC · Health Care
Invenomic Capital Management LP reported holding 1,738,790 shares of VTRS (VIATRIS INC) in its Q2 2026 13F filing — a position valued at US$27.6M, representing 1.65% of its reported portfolio and ranking #18 among its reported holdings. Invenomic Capital Management LP has disclosed VTRS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Invenomic Capital Management LP's VTRS position evolved
Invenomic Capital Management LP first disclosed a stake in VTRS in Q3 2023 at 6,952,645 shares (US$68.6M). The position peaked in Q4 2025 at 5,593,608 shares, worth US$69.6M. Across 12 filings, Invenomic Capital Management LP increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,738,790 shares valued at US$27.6M — a reduction of -1,490,322 shares quarter over quarter.. Notable position changes include a 97% increase in Q1 2025 (shares rose 3% over the following quarter), a 42% trim in Q1 2026 (shares rose 18% over the following quarter), a 46% trim in Q2 2026 (shares rose 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 6.95M | $68.55M | New |
| Q4 2023 | 5.81M | $62.95M | Reduce |
| Q1 2024 | 3.95M | $47.19M | Reduce |
| Q2 2024 | 4.29M | $45.61M | Add |
| Q3 2024 | 3.76M | $43.65M | Reduce |
| Q4 2024 | 3.26M | $40.59M | Reduce |
| Q1 2025 | 6.44M | $56.06M | Add |
| Q2 2025 | 4.64M | $41.46M | Reduce |
| Q3 2025 | 5.41M | $53.59M | Add |
| Q4 2025 | 5.59M | $69.64M | Add |
| Q1 2026 | 3.23M | $43.63M | Reduce |
| Q2 2026 | 1.74M | $27.61M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VTRS and 13F data
VTRS (VIATRIS INC) is a Health Care company. 34 other funds we track also report a position in VTRS — the largest reported positions include DAVIS SELECTED ADVISERS (US$1.19B), Rubric Capital Management LP (US$542.6M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$320.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VTRS
- DAVIS SELECTED ADVISERS 75.23M sh · $1.19B · Q2 2026
- Rubric Capital Management LP 34.17M sh · $542.60M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 20.21M sh · $320.87M · Q2 2026
- GLENVIEW CAPITAL MANAGEMENT, LLC 9.88M sh · $156.85M · Q2 2026
- Callodine Capital Management, LP 8.00M sh · $127.05M · Q2 2026
More on Invenomic Capital Management LP
FAQ
How long has Invenomic Capital Management LP held VTRS?
Invenomic Capital Management LP has disclosed VTRS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Invenomic Capital Management LP's current position in VTRS?
As of Q2 2026, Invenomic Capital Management LP holds 1.74M shares of VTRS (VIATRIS INC), valued at $27.61M, representing 1.65% of its reported portfolio and ranking #18.
Has Invenomic Capital Management LP been buying or selling VTRS?
In the latest 13F filing (Q2 2026), Invenomic Capital Management LP reduced its position in VTRS. The position peaked in Q4 2025 at 5.59M shares.
Which other funds hold VTRS?
Other major institutional holders of VTRS include DAVIS SELECTED ADVISERS, Rubric Capital Management LP, DEERFIELD MANAGEMENT COMPANY, L.P., among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.